HK1153648A1 - Methods for increasing or decreasing bone density and identifying molecules - Google Patents

Methods for increasing or decreasing bone density and identifying molecules

Info

Publication number
HK1153648A1
HK1153648A1 HK11107767.3A HK11107767A HK1153648A1 HK 1153648 A1 HK1153648 A1 HK 1153648A1 HK 11107767 A HK11107767 A HK 11107767A HK 1153648 A1 HK1153648 A1 HK 1153648A1
Authority
HK
Hong Kong
Prior art keywords
increasing
methods
bone density
identifying molecules
decreasing bone
Prior art date
Application number
HK11107767.3A
Other languages
English (en)
Inventor
Sutherland May S Kung
James C Geoghegan
Changpu Yu
John Latham
Original Assignee
Ucb Mfg Inc
Sutherland May S Kung
James C Geoghegan
Changpu Yu
John Latham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Mfg Inc, Sutherland May S Kung, James C Geoghegan, Changpu Yu, John Latham filed Critical Ucb Mfg Inc
Publication of HK1153648A1 publication Critical patent/HK1153648A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
HK11107767.3A 2002-03-01 2011-07-26 Methods for increasing or decreasing bone density and identifying molecules HK1153648A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36125802P 2002-03-01 2002-03-01
US40617102P 2002-08-27 2002-08-27
US44739303P 2003-02-13 2003-02-13

Publications (1)

Publication Number Publication Date
HK1153648A1 true HK1153648A1 (en) 2012-04-05

Family

ID=27792176

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11107767.3A HK1153648A1 (en) 2002-03-01 2011-07-26 Methods for increasing or decreasing bone density and identifying molecules

Country Status (7)

Country Link
US (3) US7332276B2 (fr)
EP (2) EP2277522B1 (fr)
JP (2) JP4662714B2 (fr)
AU (1) AU2003223214B2 (fr)
CA (1) CA2476410C (fr)
HK (1) HK1153648A1 (fr)
WO (1) WO2003073991A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2006135734A2 (fr) * 2005-06-10 2006-12-21 The Regents Of The University Of California Compositions et methodes permettant d'altérer la densité osseuse et la structuration osseuse
PL3345607T3 (pl) 2006-12-29 2023-01-09 Ossifi-Mab Llc Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise
EA200901031A1 (ru) * 2007-02-02 2010-04-30 Новартис Аг Модуляторы склеростин-связывающих партнеров для лечения костных расстройств
WO2009036368A2 (fr) 2007-09-14 2009-03-19 Nitto Denko Corporation Vecteurs de médicament
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AU2008338464A1 (en) 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
WO2010100200A2 (fr) * 2009-03-05 2010-09-10 Novartis Ag Préparation d'anticorps lyophilisée
EA027039B1 (ru) 2010-05-14 2017-06-30 Эмджен Инк. Композиции с высокой концентрацией антител
WO2011154413A1 (fr) 2010-06-07 2011-12-15 Fritz-Lipmann-Insitut E. V. Leibniz-Institut Für Altersforschung Agent contre l'ostéoporose induite par les glucocorticoïdes
JP2012072095A (ja) * 2010-09-29 2012-04-12 Tokyo Institute Of Technology 骨形成促進剤
EP3757126A1 (fr) 2010-11-05 2020-12-30 Novartis AG Méthodes de traitement de la polyarthrite psoriasique au moyen d'antagonistes d'il-17
WO2012118903A2 (fr) 2011-03-01 2012-09-07 Amgen Inc. Agents liants bispécifiques
CN103517920B (zh) 2011-03-25 2018-04-17 安进公司 抗硬化蛋白(sclerostin)抗体晶体及其制剂
JP2014515759A (ja) 2011-04-29 2014-07-03 ノバルティス アーゲー 扁平上皮がんを治療する方法関連出願
PT2739311T (pt) 2011-08-04 2018-03-26 Amgen Inc Método para tratamento de defeitos de lacunas ósseas
EP2797953B1 (fr) 2011-12-28 2020-06-03 Amgen Inc. Méthode de traitement d'une perte osseuse alvéolaire au moyen d'anticorps anti-sclérostine
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (fr) 2013-01-31 2014-08-07 Novartis Ag Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine
WO2014155278A2 (fr) 2013-03-26 2014-10-02 Novartis Ag Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
MX2017011399A (es) * 2015-03-09 2018-03-16 Intercept Pharmaceuticals Inc Métodos para modular la densidad ósea.
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2018115879A1 (fr) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Utilisation d'anticorps anti-sclérostine dans le traitement de l'ostéogenèse imparfaite
US11498961B2 (en) 2017-07-27 2022-11-15 Jiangsu Hengrui Medicine Co., Ltd. SOST antibody pharmaceutical composition and uses thereof
KR20200138254A (ko) 2018-03-30 2020-12-09 암젠 인크 C-말단 항체 변이체
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
CN111658821A (zh) * 2020-06-03 2020-09-15 深圳市百吉因生物科技有限公司 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
DE3441148A1 (de) 1984-11-10 1986-05-15 Wella Ag, 6100 Darmstadt Oxidationshaarfaerbemittel auf der basis von 4-amino-2-hydroxyalkylphenolen
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
LU86905A1 (fr) 1987-05-29 1989-01-19 Oreal Nouvelles metaphenylenediamines,leur procede de preparation,composes intermediaires et utilisation de ces metaphenylenediamines en tant que coupleurs pour la teinture d'oxydation des fibres keratiniques et en particulier des cheveux humains
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
FR2649887B1 (fr) 1989-07-21 1994-07-08 Oreal Procede de coloration mettant en oeuvre des colorants indoliques et des precurseurs de colorants d'oxydation et agents de teinture mis en oeuvre
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP0752885B1 (fr) 1992-09-25 2003-07-09 Neorx Corporation Inhibiteur therapeutique de cellules des muscles vasculaires lisses
US5382587A (en) 1993-06-30 1995-01-17 Merck & Co., Inc. Spirocycles
AU688428B2 (en) 1993-11-09 1998-03-12 Johns Hopkins University, The Generation of high titers of recombinant AAV vectors
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
WO1997040137A1 (fr) * 1996-04-19 1997-10-30 Osiris Therapeutics, Inc. Regeneration et croissance osseuse obtenues a l'aide de cellules souches du mesenchyme
US6541258B2 (en) 1996-12-18 2003-04-01 Targeted Genetics Corporation AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
CA2304168A1 (fr) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Procedes et lignee cellulaire utiles pour la production de virus adeno-associes recombines
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999041399A1 (fr) 1998-02-17 1999-08-19 Genzyme Corporation Procedes de fabrication de vecteurs purifies des virus associees aux adenovirus
US5980584A (en) 1998-11-03 1999-11-09 Bristol-Myers Squibb Company Substituted p-aminophenol, process of preparation and use in dyeing hair
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
AU2223600A (en) * 1999-01-06 2000-07-24 Cedars-Sinai Medical Center Hormone replacement for breast cancer patients
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
AU4851900A (en) * 1999-06-09 2000-12-28 Genentech Inc. Compositions and methods for the treatment of tumor
AU776609B2 (en) * 1999-09-24 2004-09-16 Novartis Ag Topical suspension formulations containing ciprofloxacin and dexamethasone
CA2284103A1 (fr) * 1999-09-30 2001-03-30 Edith Bonnelye Recepteur des oestrogenes, err.alpha, un regulateur de la formation osseuse
US6342079B1 (en) 2000-01-27 2002-01-29 Bristol-Myers Squibb Company Primary intermediate for use in oxidative hair dyeing
WO2001092308A2 (fr) * 2000-06-01 2001-12-06 Amgen, Inc. Polypeptides a noeud de cystines: molecules 'cloaked-2' et leurs utilisations
JP2004520005A (ja) * 2000-06-19 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー オステオレビン遺伝子多型性
DE20013155U1 (de) 2000-07-28 2000-10-12 Wella Ag 2,5-Diamino-1-(1'-hydroxyalkyl-)benzol-Derivate enthaltende Färbemittel für Keratinfasern
TR200401292T3 (tr) * 2000-12-01 2004-07-21 Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften RNAÁgirişimineÁyolÁaçanÁküçükÁRNAÁmolekülleri
JP2005503801A (ja) * 2001-09-21 2005-02-10 ユニバーシティー オブ ロチェスター 幹細胞／前駆細胞の自己再生および分化の概日制御方法、ならびに時計制御遺伝子発現の概日制御方法
US20030186915A1 (en) * 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof

Also Published As

Publication number Publication date
US7655420B2 (en) 2010-02-02
EP2277522A2 (fr) 2011-01-26
WO2003073991A3 (fr) 2007-02-22
WO2003073991A2 (fr) 2003-09-12
CA2476410C (fr) 2013-09-24
US7332276B2 (en) 2008-02-19
AU2003223214A1 (en) 2003-09-16
US20080227138A1 (en) 2008-09-18
EP1575481A4 (fr) 2010-01-06
EP2277522A3 (fr) 2011-04-20
US20030229041A1 (en) 2003-12-11
JP2005532998A (ja) 2005-11-04
EP2277522B1 (fr) 2012-11-21
CA2476410A1 (fr) 2003-09-12
AU2003223214B2 (en) 2008-09-18
EP1575481A2 (fr) 2005-09-21
JP2010213708A (ja) 2010-09-30
US8227441B2 (en) 2012-07-24
JP4662714B2 (ja) 2011-03-30
US20110009467A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
HK1153648A1 (en) Methods for increasing or decreasing bone density and identifying molecules
EP1552002A4 (fr) Molecules toxine-aptamere et procedes d'utilisation correspondants
EP1680177A4 (fr) Systeme d'acces chirurgical et procedes correspondant
EP1868517A4 (fr) Plaque pour os et procede d'utilisation de la plaque pour os
EP1556057A4 (fr) Agents et procedes pour stimuler la formation osseuse
EP1595147A4 (fr) Procede et systeme d'analyse
EP1617772A4 (fr) Systeme de stabilisation de lame osseuse et sa methode d'utilisation
AU2003247751A8 (en) Total disc replacement system and related methods
EP1472098A4 (fr) Procede et appareil anti-contrefacon de controle de monnaie
GB0225290D0 (en) Anti-counterfeiting apparatus and method
GB0307406D0 (en) Data analysis system and method
HK1121574A1 (en) Recording and/or reproducing apparatus
EP1629387A4 (fr) Procedes et appareil fournissant des informations d'etat d'antememoire
HK1108204A1 (en) Recording and/or reproducing apparatus
GB0300906D0 (en) Secure physical documentsw and methods and apparatus fo publishing and reading them
IL173787A0 (en) Methods and systems for profiling biological systems
EP1638977A4 (fr) Salinosporamides et leurs methodes d'utilisation
EP1475766A4 (fr) Moyen d'identification et procede d'identification d'un objet
EP1624791A4 (fr) Methode et systeme de modelage d'une structure osseuse
AU2003268032A8 (en) Composition and methods for treatment and screening
IL172704A0 (en) Salinosporamides and methods for use thereof
AU2003238655A8 (en) Method and apparatus for determining tissue viability
EP1649809A4 (fr) Dispositif et procede servant a evaluer la densite des mineraux osseux
HK1101537A1 (en) Surgical instrument and method
EP1660671A4 (fr) Procedes de detection et d'identification de composes

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200225